Publications 2010-2022

Publications 2014–2015–2016–2017–2018–2019–2020-2022

2020-2022 (return)

  1. Rossi, J.-F.; Chiang, H.-C.; Lu, Z.-Y.; Levon, K.; van Rhee, F.; Kanhai, K.; Fajgenbaum, D. C. and Klein, B. (2022). Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling., Frontiers in immunology 13 : 919489.
  2. Rossi, J.-F.; Chiang, H.-C. and Klein, B. (2021). Tocilizumab in Treatment for Patients With COVID-19., JAMA internal medicine 181 : 1018-1019.
  3. Villard, O.; Armanet, M.; Couderc, G.; Bony, C.; Moreaux, J.; Noël, D.; De Vos, J.; Klein, B.; Veyrune, J.-L. and Wojtusciszyn, A. (2020). Characterization of immortalized human islet stromal cells reveals a MSC-like profile with pancreatic features., Stem cell research & therapy 11 : 158.

2019 (return)

  1. Requirand, G.; Robert, N.; Boireau, S.; Vincent, L.; Seckinger, A.; Bouhya, S.; Ceballos, P.; Cartron, G.; Hose, D.; Klein, B. and Moreaux, J. (2019). BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma., Cytometry. Part B, Clinical cytometry 96 : 209-214.
  2. Vikova, V.; Jourdan, M.; Robert, N.; Requirand, G.; Boireau, S.; Bruyer, A.; Vincent, L.; Cartron, G.; Klein, B.; Elemento, O.; Kassambara, A. and Moreaux, J. (2019). Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance., Theranostics 9 : 540-553.
  3. Gourzones, C.; Bellanger, C.; Lamure, S.; Gadacha, O. K.; De Paco, E. G.; Vincent, L.; Cartron, G.; Klein, B. and Moreaux, J. (2019). Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells., Cancers 11.

2018 (return)

  1. Alaterre, E.; Raimbault, S.; Garcia, J.-M.; Rème, T.; Requirand, G.; Klein, B. and Moreaux, J. (2018). Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry., Cytometry. Part B, Clinical cytometry 94 : 484-492.
  2. Bruyer, A.; Maes, K.; Herviou, L.; Kassambara, A.; Seckinger, A.; Cartron, G.; Rème, T.; Robert, N.; Requirand, G.; Boireau, S.; Müller-Tidow, C.; Veyrune, J.-L.; Vincent, L.; Bouhya, S.; Goldschmidt, H.; Vanderkerken, K.; Hose, D.; Klein, B.; De Bruyne, E. and Moreaux, J. (2018). DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells., British journal of cancer 118 : 1062-1073.

2017 (return)

  1. Jourdan, M.; Robert, N.; Cren, M.; Thibaut, C.; Duperray, C.; Kassambara, A.; Cogné, M.; Tarte, K.; Klein, B. and Moreaux, J. (2017). Characterization of human FCRL4-positive B cells., PloS one 12 : e0179793.
  2. Kassambara, A.; Jourdan, M.; Bruyer, A.; Robert, N.; Pantesco, V.; Elemento, O.; Klein, B. and Moreaux, J. (2017). Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell., Nucleic acids research 45 : 5639-5652.
  3. Schoenhals, M.; Jourdan, M.; Bruyer, A.; Kassambara, A.; Klein, B. and Moreaux, J. (2017). Hypoxia favors the generation of human plasma cells., Cell cycle (Georgetown, Tex.) 16 : 1104-1117.
  4. Alaterre, E.; Raimbault, S.; Goldschmidt, H.; Bouhya, S.; Requirand, G.; Robert, N.; Boireau, S.; Seckinger, A.; Hose, D.; Klein, B. and Moreaux, J. (2017). CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma., Oncotarget 8 : 98931-98944.
  5. Viziteu, E.; Klein, B.; Basbous, J.; Lin, Y.-L.; Hirtz, C.; Gourzones, C.; Tiers, L.; Bruyer, A.; Vincent, L.; Grandmougin, C.; Seckinger, A.; Goldschmidt, H.; Constantinou, A.; Pasero, P.; Hose, D. and Moreaux, J. (2017). RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma., Leukemia 31 : 2104-2113.

2016 (return)

  1. Viziteu, E.; Grandmougin, C.; Goldschmidt, H.; Seckinger, A.; Hose, D.; Klein, B. and Moreaux, J. (2016). Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma., British journal of cancer 114 : 519-23.
  2. Viziteu, E.; Kassambara, A.; Pasero, P.; Klein, B. and Moreaux, J. (2016). RECQ helicases are deregulated in hematological malignancies in association with a prognostic value., Biomarker research 4 : 3.
  3. Herviou, L.; Cavalli, G.; Cartron, G.; Klein, B. and Moreaux, J. (2016). EZH2 in normal hematopoiesis and hematological malignancies., Oncotarget 7 : 2284-96.
  4. Jourdan, M.; Cren, M.; Schafer, P.; Robert, N.; Duperray, C.; Vincent, L.; Ceballos, P.; Cartron, G.; Rossi, J.-F.; Moreaux, J.; Chopra, R. and Klein, B. (2016). Differential effects of lenalidomide during plasma cell differentiation., Oncotarget 7 : 28096-111.
  5. Schoenhals, M.; Jourdan, M.; Seckinger, A.; Pantesco, V.; Hose, D.; Kassambara, A.; Moreaux, J. and Klein, B. (2016). Forced KLF4 expression increases the generation of mature plasma cells and uncovers a network linked with plasma cell stage., Cell cycle (Georgetown, Tex.) 15 : 1919-28.

2015 (return)

  1. Bolomsky, A.; Hose, D.; Schreder, M.; Seckinger, A.; Lipp, S.; Klein, B.; Heintel, D.; Ludwig, H. and Zojer, N. (2015). Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma., Journal of hematology & oncology 8 : 10.
  2. Bret, C.; Klein, B.; Cartron, G.; Schved, J.-F.; Constantinou, A.; Pasero, P. and Moreaux, J. (2015). DNA repair in diffuse large B-cell lymphoma: a molecular portrait., British journal of haematology 169 : 296-9.
  3. Hassen, W.; Kassambara, A.; Reme, T.; Sahota, S.; Seckinger, A.; Vincent, L.; Cartron, G.; Moreaux, J.; Hose, D. and Klein, B. (2015). Drug metabolism and clearance system in tumor cells of patients with multiple myeloma., Oncotarget 6 : 6431-47.
  4. Kassambara, A.; Rème, T.; Jourdan, M.; Fest, T.; Hose, D.; Tarte, K. and Klein, B. (2015). GenomicScape: an easy-to-use web tool for gene expression data analysis. Application to investigate the molecular events in the differentiation of B cells into plasma cells., PLoS computational biology 11 : e1004077.
  5. Maes, K.; De Smedt, E.; Kassambara, A.; Hose, D.; Seckinger, A.; Van Valckenborgh, E.; Menu, E.; Klein, B.; Vanderkerken, K.; Moreaux, J. and De Bruyne, E. (2015). In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma., Oncotarget 6 : 3319-34.
  6. Rossi, J.-F.; Lu, Z.-Y.; Jourdan, M. and Klein, B. (2015). Interleukin-6 as a therapeutic target., Clinical cancer research : an official journal of the American Association for Cancer Research 21 : 1248-57.
  7. Seckinger, A.; Meißner, T.; Moreaux, J.; Benes, V.; Hillengass, J.; Castoldi, M.; Zimmermann, J.; Ho, A. D.; Jauch, A.; Goldschmidt, H.; Klein, B. and Hose, D. (2015). miRNAs in multiple myeloma–a survival relevant complex regulator of gene expression., Oncotarget 6 : 39165-83.
  8. Vincent, L.; Ceballos, P.; Plassot, C.; Méniane, J. C.; Quittet, P.; Navarro, R.; Cyteval, C.; Szablewski, V.; Lu, Z. Y.; Kanouni, T.; Moreaux, J.; Cartron, G.; Klein, B. and Fegueux, N. (2015). Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma., Blood cancer journal 5 : e341.
  9. Waizenegger, J. S.; Ben-Batalla, I.; Weinhold, N.; Meissner, T.; Wroblewski, M.; Janning, M.; Riecken, K.; Binder, M.; Atanackovic, D.; Taipaleenmaeki, H.; Schewe, D.; Sawall, S.; Gensch, V.; Cubas-Cordova, M.; Seckinger, A.; Fiedler, W.; Hesse, E.; Kröger, N.; Fehse, B.; Hose, D.; Klein, B.; Raab, M. S.; Pantel, K.; Bokemeyer, C. and Loges, S. (2015). Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma., Leukemia 29 : 696-704.
  10. Weinhold, N.; Meissner, T.; Johnson, D. C.; Seckinger, A.; Moreaux, J.; Försti, A.; Chen, B.; Nickel, J.; Chubb, D.; Rawstron, A. C.; Doughty, C.; Dahir, N. B.; Begum, D. B.; Young, K.; Walker, B. A.; Hoffmann, P.; Nöthen, M. M.; Davies, F. E.; Klein, B.; Goldschmidt, H.; Morgan, G. J.; Houlston, R. S.; Hose, D. and Hemminki, K. (2015). The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells., Haematologica 100 : e110-3.

2014 (return)

  1. Auger, S.; Orsini, M.; Céballos, P.; Fegueux, N.; Kanouni, T.; Caumes, B.; Klein, B.; Villalba, M. and Rossi, J.-F. (2014). Controlled Epstein-Barr virus reactivation after allogeneic transplantation is associated with improved survival., European journal of haematology 92 : 421-8.
  2. Bou Samra, E.; Klein, B.; Commes, T. and Moreaux, J. (2014). Identification of a 20-gene expression-based risk score as a predictor of clinical outcome in chronic lymphocytic leukemia patients., BioMed research international 2014 : 423174.
  3. Jourdan, M.; Cren, M.; Robert, N.; Bolloré, K.; Fest, T.; Duperray, C.; Guilloton, F.; Hose, D.; Tarte, K. and Klein, B. (2014). IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors., Leukemia 28 : 1647-56.
  4. Kassambara, A.; Gourzones-Dmitriev, C.; Sahota, S.; Rème, T.; Moreaux, J.; Goldschmidt, H.; Constantinou, A.; Pasero, P.; Hose, D. and Klein, B. (2014). A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy., Oncotarget 5 : 2487-98.
  5. Moreaux, J.; Bruyer, A.; Veyrune, J.-L.; Goldschmidt, H.; Hose, D. and Klein, B. (2014). DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine., British journal of haematology 164 : 613-6.
  6. Wagner, V.; Hose, D.; Seckinger, A.; Weiz, L.; Meißner, T.; Rème, T.; Breitkreutz, I.; Podar, K.; Ho, A. D.; Goldschmidt, H.; Krämer, A.; Klein, B. and Raab, M. S. (2014). Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1., Oncotarget 5 : 10237-50.
  7. Waizenegger, J. S.; Ben-Batalla, I.; Weinhold, N.; Meissner, T.; Wroblewski, M.; Janning, M.; Riecken, K.; Binder, M.; Atanackovic, D.; Taipaleenmaeki, H.; Schewe, D.; Sawall, S.; Gensch, V.; Cubas-Cordova, M.; Seckinger, A.; Fiedler, W.; Hesse, E.; Kröger, N.; Fehse, B.; Hose, D.; Klein, B.; Raab, M. S.; Pantel, K.; Bokemeyer, C. and Loges, S. (2015). Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma., Leukemia 29 : 696-704.